Industry News

News from Freeline

2023-04-07T16:08:54+02:00

Freeline has made the difficult decision to not progress our Fabry disease program further

News from Freeline2023-04-07T16:08:54+02:00

News from Sanofi

2023-03-17T13:47:28+01:00

Orphanet Journal of Rare Diseases recently published an in-depth history of the Sanofi Rare Disease Registries.

News from Sanofi2023-03-17T13:47:28+01:00

Sad news from Fabry Korea

2023-03-17T13:41:33+01:00

It is with great sadness that we learned of the passing of BongKi Lim, Fabry Korea's chairman for the past 22 years. 

Sad news from Fabry Korea2023-03-17T13:41:33+01:00

News from Sangamo

2023-03-17T10:55:07+01:00

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for Pegunigalsidase Alfa for Treatment of Fabry Disease.

News from Sangamo2023-03-17T10:55:07+01:00

News from Chiesi

2023-03-17T10:18:35+01:00

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for Pegunigalsidase Alfa for Treatment of Fabry Disease.

News from Chiesi2023-03-17T10:18:35+01:00

News from Sangamo Therapeutics

2022-02-08T16:29:44+01:00

Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated α-Gal A Enzyme Activity in Patients With Fabry Disease

News from Sangamo Therapeutics2022-02-08T16:29:44+01:00

News from Freeline

2021-12-13T18:27:08+01:00

Freeline announced new data from its ongoing Phase 1/2 MARVEL-1 dose-finding clinical trial of FLT190 for the treatment of Fabry disease and provided updates on its pipeline programs. 

News from Freeline2021-12-13T18:27:08+01:00

News from Idorsia

2021-12-13T18:15:52+01:00

Idorsia Ltd (SIX: IDIA) today announced that after the planned interim analysis of the open-label extension (OLE) of the Phase 3 MODIFY study with lucerastat for the treatment of adult patients with Fabry disease, the study will continue.

News from Idorsia2021-12-13T18:15:52+01:00
Go to Top